Startup · $12m raised
Melbourne, VIC
Programs: Brandon BioCatalyst (CUREator)
Every investor coverage indicates participated in a round Currus Biologics raised.
| Investor | Rounds | Invested |
|---|---|---|
| Brandon BioCatalyst | Accelerator · Grant | - |
| Brandon Capital | Series A | - |
| Brandon Capital Partners | Series A | - |
| Main Sequence Ventures | undisclosed | - |
| Medical Research Commercialisation Fund (MRCF) | Series A | - |
| Uniseed | Series A | - |
Companies Currus Biologics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Alessandra Cesano | Chair of the Board | Mirage News, Brandon BioCatalyst portfolio, Uniseed |
| Dr Clare Slaney | BEAT Inventor (former) | Brandon BioCatalyst, Main Sequence |
| Dr Michael Bettess | Chairman | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
| Dr Mike Kershaw | Founder | Brandon BioCatalyst |
| Dr Mike Kershaw | Founder | Main Sequence |
| Dr Swami Murugappan | Chief Medical Officer | Mirage News, Brandon BioCatalyst portfolio, Uniseed |
| Ebony Heyns | Founder | Main Sequence |
| Sam Cobb | CEO · Founder | Mirage News, Brandon BioCatalyst portfolio (Tue 29 Sep 2026), Uniseed, Brandon BioCatalyst, Main Sequence, Brandon Capital portfolio (Mon 28 Jun 2021), Brandon BioCatalyst portfolio (Mon 28 Jun 2021), Brandon BioCatalyst portfolio (Mon 28 Jun 2021), Brandon Capital portfolio (Mon 28 Jun 2021) |
Stories naming Currus Biologics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Profile of deep tech investor Main Sequence covering Elaine Stead's promotion to Partner, portfolio unicorns Gilmour Space and Advanced Navigation, CSIRO's expanded Atmosphere backing, and a fourth fund now being raised.
Main Sequence announces Elaine Stead's promotion to Partner while preparing its fourth fund; CSIRO has lifted its commitment to the firm's Atmosphere pre-seed program, and two portfolio companies have reached unicorn status.
America's medicines regulator has approved Currus Biologics to begin human trials of CUR-001, its solid-tumour CAR T-cell therapy combination, with dosing expected from early 2027.
Australian biotech Currus Biologics has won US regulator clearance to begin human testing of its lead cancer therapy, CUR-001; the company's backers include Brandon Capital, Main Sequence and Uniseed.
Australian biotech Currus Biologics has won US regulatory clearance to begin human testing of its lead cancer therapy, CUR-001, combining an antibody platform with CAR T cells for solid tumours.
Brandon Capital has put roughly $60 million of National Reconstruction Fund money into ten biotech companies and warns R&D tax changes would hurt deep tech; portfolio company Myricx Bio went to Novartis.
Also australiatimes.com
Profile of a Peter Mac spinout advancing solid-tumour cell therapies; recounts its Series A backers, later investment, grant support, and chief executive Sam Cobb's earlier career building and listing AdAlta.
Main Sequence explains why it backed Currus Biologics, whose BEAT platform aims to make CAR-T cell therapies effective against solid tumours, starting with mesothelin-positive cancers, as the team prepares for a clinical trial.
Eight Australian health startups received equity-free grants totaling 18.5 million dollars from the CUREator+ program, supported by government funding and delivered with partners Brandon BioCatalyst and ANDHealth.
CUREator, Brandon BioCatalyst's government-backed grant program, has awarded $7.21 million across eight Australian biotech firms in its newest round, split between clinical-stage and preclinical recipients.
Also Brandon BioCatalyst portfolio·Startup Daily·ausceleratesa.org
Brandon BioCatalyst's CUREator incubator names its first-round awardees, distributing government-backed funding across 23 Australian life science companies working on treatments from schizophrenia to diabetes, with round two applications now open.
The CUREator incubator, run by Brandon BioCatalist's partner organisation, names its first-round awardees, distributing government-backed grant funding across 23 Australian life science companies developing treatments for diseases including diabetes, cancer and COPD.
Ignition Lane's weekly technology roundup: climate-tech funding activity, Grok's bid for AGL, King River Capital's digital asset fund, a batch of Australian startup raises, Maropost acquisitions, GigSuper's collapse and a National AI Centre appointment.
Also Startup Daily
Startup Daily reports the inaugural Governor of Victoria Startup Awards, where Amber Electric and Seer Medical shared the top prize, Linktree took scaleup honours, and the Allens' Tractor Ventures won investor recognition.
Also Startup Daily
Weekly roundup reporting Gilmour Space's raise, several startup funding rounds, KKR's Education Perfect deal, ASX listings, new funds from Accel and the Albert family, and global tech listings and acquisitions.
Also Forbes Australia
Weekly roundup of Australian startup funding: Gilmour Space's $61m raise, rounds for Mindset Health, HowToo, Beer Cartel, Tracer DAO and Wimp 2 Warrior, Currus Biologics' $10m cancer-treatment raise, and Alberts' $16m impact fund.
Also Startup Daily·Startup Daily·Startup Daily·Startup Daily
Melbourne cancer immunotherapy startup Currus Biologics, spun out of Peter MacCallum, raised $10 million led by the Brandon Capital-managed Medical Research Commercialisation Fund with Uniseed, to advance its BEAT technology toward human trials.
Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·SmartCompany·Startup Daily·SmartCompany·Startup Daily